Gilead disclosed a partial clinical hold impacting two CAR-T cell therapy trials after cases of ICANS, a neurological toxicity associated with CAR-T. The company’s move underscores how safety events can quickly alter development timelines for advanced immunotherapies. Separate reporting also ties Gilead’s CAR-T program disruptions to downstream schedule effects, reflecting the operational burden sponsors face when managing neurotoxicity signals in complex cell therapy workflows. The update matters to biotech investors and partners because partial holds can change site enrollment, study endpoints, and ultimately label and market-access timelines for next-generation cellular therapies.